目的 研究非甲基化CpG基序的寡聚脱氧核苷酸 (CpG ODN)联合热休克蛋白70(HSP70)/CD80DNA疫苗对哮喘小鼠肺部炎症、血清IL-4、IL-13、IFN-γ及支气管肺泡灌洗液(BALF)中IL-4、IL-25、IL-33水平变化的影响,为联合 CpG ODN -HSP70/CD80 DNA疫苗治疗哮喘提供实验依据。方法 2019年6-9月选用 6~8周龄BALB/c小鼠32只, 卵清蛋白(OVA)加氢氧化铝[Al(OH)3]佐剂致敏的方法制备小鼠哮喘模型, 随机分成4组,分别为对照组、哮喘组、HSP70/CD80DNA疫苗组及联合疫苗组(CpG ODN联合HSP70/CD80DNA疫苗组),HE染色观察肺组织病理形态学改变,ELISA法检测血清IL-4、IL-13、IFN-γ和BALF中IL-4、IL-25、IL-33水平变化。结果 肺组织HE染色结果显示HSP70/CD80疫苗联合CpG ODN治疗组小鼠肺组织炎症反应较哮喘组明显减轻,气道周围炎症细胞浸润显著减少。ELISA结果显示与对照组比较,哮喘组血清IL-4及IL-13水平显著增高(P<0.05),血清IFN-γ水平明显下降(P<0.05);与哮喘组比较,HSP70/CD80DNA疫苗组和联合疫苗组血清IL-4及IL-13水平显著降低(P<0.05),血清IFN-γ水平明显升高(P<0.05);与HSP70/CD80DNA疫苗组比较,联合疫苗组血清IL-4及IL-13水平显著降低(P<0.05),血清IFN-γ水平明显升高(P<0.05);支气管肺泡灌洗液(BALF)结果显示与对照组比较,哮喘组BALF IL-4、IL-25、IL-33水平显著增高(P<0.05);与哮喘组比较,HSP70/CD80DNA疫苗组和联合疫苗组BALF IL-4、IL-25、IL-33水平显著下降(P<0.05);与HSP70/CD80DNA疫苗组比较,联合疫苗组BALF IL-4、IL-25、IL-33水平显著降低(P<0.05)。结论 CpG ODN联合HSP70/CD80DNA疫苗能抑制小鼠体内产生IL-4、IL-13、IL-25、IL-33, 增强小鼠体内产生IFN-γ,减轻哮喘小鼠气道炎症。
Abstract
Objective To study the effect of non-methylated CpG oligodeoxynucleotide (cytosine-phosphate-guanosine-oligodeoxynucleotides, CpG ODN) combined with heat shock protein 70 (heat shock protein 70, HSP70)/CD80DNA vaccine on pulmonary inflammation, serum levels of IL-4, IL-13, IFN-γ and the changes of IL-4, IL-25 and IL-33 in bronchoalveolar lavage fluid(BALF) of asthmatic mice, so as to provide experimental basis for the treatment of asthma by CpG ODN-HSP70/CD80DNA vaccine. Methods Ovalbumin (OVA) and aluminum hydroxide [Al (OH)3] adjuvant were used to sensitize mice with asthma model.From June to September 2019,totally 32 BALB/c mice aged 6—8 weeks were selected and were randomly divided into four groups, including control group, asthma group, HSP70/CD80DNA vaccine group and combined vaccine group (CpG ODN combined with HSP70/CD80DNA vaccine group).HE staining was used to observe the pathological and morphological changes of lung tissue.The changes of serum levels of IL-4, IL-13, IFN-γ in and IL-4, IL-25, IL-33 in BALF were detected by ELISA. Results HE staining of lung tissue showed that the inflammatory response of lung tissue in combined vaccine group was significantly less than that in the asthma group, and the infiltration of inflammatory cells around the airway was significantly reduced.ELISA results showed that compared with the control group, serum levels of IL-4 and IL-13 in asthma group were significantly higher (P<0.05), and serum IFN-γ level was significantly lower (P<0.05).Compared with the asthma group, serum levels of IL-4 and IL-13 in the Hsp70/CD80DNA vaccine group and the combined vaccine group were significantly lower (P<0.05), and the serum IFN-γ level was significantly higher (P<0.05).Compared with the Hsp70/CD80DNA vaccine group, the serum levels of IL-4 and IL-13 in combined vaccine group were significantly decreased (P<0.05), and the serum IFN-γ were significantly increased (P<0.05).The results of BALF showed that compared with the control group, the levels of BALF IL-4, IL-25 and IL-33 in the asthma group were significantly increased (P<0.05).Compared with the asthma group, the levels of IL-4, IL-25 and IL-33 in BALF in the Hsp70/CD80 DNA vaccine group and the combined vaccine group were significantly decreased (P<0.05).And the levels of IL-33 in BALF in the combined vaccine group were significantly lower than those in the Hsp70/CD80 DNA vaccine group (P<0.05). Conclusion CpG ODN combined with Hsp70/CD80DNA vaccine can inhibit the production of IL-4, IL-13, IL-25 and IL-33 in mice, enhance the production of IFN-γ in mice, and reduce airway inflammation in asthmatic mice.
关键词
HSP70/CD80DNA疫苗 /
CpG ODN /
气道炎症 /
哮喘小鼠
Key words
HSP70/CD80DNA vaccine /
CpG ODN /
airway inflammation /
asthmatic mice
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Poon AH, Eidelman DH, Martin JG, et al.Pathogenesis of severe asthma[J].Clin Exp Allergy,2012, 42(5):625-637.
[2] Evasovic JM, Singer CA.Regulation of IL-17A and implications for TGF-β1 comodulation of airway smooth muscle remodeling in severe asthma[J].Am J Physiol Lung Cell Mol Physiol,2019,316(5):L843-L868.
[3] Zhang L, Lasmar LB, Castro-Rodriguez JA.The impact of asthma and its treatment on growth: an evidence-based review[J].J Pediatr (Rio J),2019,95 (Suppl 1):10-22.
[4] 侯伟,刘海燕,杨旭东,等.氧化苦参碱对哮喘小鼠肺组织中TGF-β1及AngII表达的影响[J].中国儿童保健杂志,2010,18(2):135-143.
[5] Casaro M, Souza VR, Oliveira FA, et al.OVA-induced allergic airway inflammation mouse model[J].Methods Mol Biol,2019,1916:297-301.
[6] Muehling LM, Lawrence MG, Woodfolk JA.Pathogenic CD4+ T cells in patients with asthma[J].J Allergy Clin Immunol,2017,140(6):1523-1540.
[7] Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al.Macrophage plasticity, polarization, and function in health and disease[J].J Cell Physiol,2018,233(9):6425-6440.
[8] 赖欣,王丽丽,龚娅琼,等.CpG ODN在免疫佐剂中的研究新进展[J].药物生物技术,2019,26(1):73-77.
[9] Givens BE, Geary SM, Salem AK.Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma[J].Immunotherapy,2018,10(7):595-604.
[10] Kim DH,Sohn JH,Park HJ,et al.CpG Oligodeoxynucleotide inhibits cockroach-induced asthma via induction of IFN-γ + Th1 cells or Foxp3 + regulatory T cells in the lung[J].Allergy Asthma Immunol Res,2016,8(3):264-275.
[11] Wachstein J, Tischer S, Figueiredo C, et al.Hsp70 enhances immunosuppressive function of CD4(+)CD25(+) FoxP3(+) Tregulatory cells and cytotoxicity in CD4(+)CD25(-) T cells [J].PloS One,2012,7(12):51747-51777.
[12] 李燕,谢敏,史小玲,等.HSP70/CD80 DNA疫苗通过调节Th1/Th2/Treg/Th17细胞对急性哮喘的抑制作用[J].山东大学学报:医学版,2014,10(52):20-24.
[13] Yao X, Sun Y, Wang W, et al.Interleukin (IL)-25: Pleiotropic roles inasthma[J].Respirology.2016,21(4):638-647.
[14] Johansson K, McSorley HJ.Interleukin-33 in the developing lung-Roles in asthma and infection[J].Pediatr Allergy Immunol,2019,30(5):503-510.
[15] Mitchell PD, O′Byrne PM.Epithelial-derived cytokines in asthma[J].Chest,2017,151(6):1338-1344.
[16] 李征,刘晔,李春阳.减毒活疫苗的应用及其研究进展[J].中国生物制品学杂志,2018,31(2):205-209.
[17] Francis MJ.Recent advances in vaccine technologies[J].Vet Clin North Am Small Anim Pract,2018,48(2):231-241.
[18] 喻吉,林彩,李海波,等.人用疫苗佐剂及其免疫学机制研究现状[J].免疫学杂志,2018,34(9):811-817.
[19] Shi S, Zhu H, Xia X, et al.Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity[J].Vaccine,2019,37(24):3167-3178.
[20] Reed SG, Orr MT, Fox CB.Key roles of adjuvants in modern vaccines[J] .Nat Med, 2013, 19(12): 1597-1608.
[21] Salem AK.A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies[J].Immuno-therapy,2014,6(11):1161-1163.
PDF(1612 KB)
